Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic-Reference-Cited by-同舟云学术

Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

Published:2022-04-24 Issue: Volume: Page:172-199
ISSN:2692-3114
Container-title:Exploration of Targeted Anti-tumor Therapy
language:
Short-container-title:

Author:

Skolariki Aglaia¹^ORCID,D’Costa Jamie¹^ORCID,Little Martin²^ORCID,Lord Simon¹^ORCID

Affiliation:

1. Department of Oncology, University of Oxford, Churchill Hospital, OX3 7LE Oxford, UK

2. Department of Oncology, Churchill Hospital, OX3 7LE Oxford, UK

Abstract

The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.

Publisher

Open Exploration Publishing

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference193 articles.

1. Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet. 2017;389:2403–14.

2. Walsh EM, Smith KL, Stearns V. Management of hormone receptor-positive, HER2-negative early breast cancer. Semin Oncol. 2020;47:187–200.

3. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13:195–203.

4. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–35.

5. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature. 1988;332:644–6.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophages Promote Subtype Conversion and Endocrine Resistance in Breast Cancer;Cancers;2024-02-05

2. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer;Biomedicine & Pharmacotherapy;2023-12

3. Effect of Calcitriol in Inhibiting the Cancer Cell Growth and Promoting Apoptosis in ErbB2-positive Breast Cancer Cells;Anti-Cancer Agents in Medicinal Chemistry;2023-11

4. Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib;International Journal of Toxicology;2023-09-04

5. WD repeat protein 54-mediator of ErbB2-driven cell motility 1 axis promotes bladder cancer tumorigenesis and metastasis and impairs chemosensitivity;Cancer Letters;2023-03